4th Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$970,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.

LobbyistCovered position, as disclosed
HANNAH BETH CORNWELL —
ERIN MENDELSOHN —
KRISTIN RICHTER —
MATTHEW O SCHUMAKER —
SWARNA VALLURUPALLI —

Contacted: SENATE; Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES

Bills named: H.R. 830 (118th), S. 1375 (118th)

Medicare/Medicaid MMM

Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.

LobbyistCovered position, as disclosed
HANNAH BETH CORNWELL —
ERIN MENDELSOHN —
KRISTIN RICHTER —
MATTHEW O SCHUMAKER —
SWARNA VALLURUPALLI —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7421 (118th), S. 3832 (118th)

Taxation/Internal Revenue Code TAX

Corporate tax reform.

LobbyistCovered position, as disclosed
SWARNA VALLURUPALLI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.